FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT	OF CH	<b>ANGES</b>	IN BEI	NEFICIAL	<b>OWNER</b>	SHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response	: 0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LINDAHL RICHARD S</u>				2. Issuer Name and Ticker or Trading Symbol Compass Therapeutics, Inc. [ CMPX ]					(Ch	Relationship of Reporting Person(s) to Issu (Check all applicable)     X Director 10% Own						
(Last)	(Fi	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 04/21/2023						_	(give title	Other (s below)	pecify		
C/O COMPASS THERAPEUTICS, INC. 80 GUEST STREET, SUITE 601			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	ndividual or Joint/Group Filing (Check Applicable 2) X Form filed by One Reporting Person						
(Street)	N M	A	02135											led by More tha	•	
(City)	(Si	tate)	(Zip)	_ R	ule '	10b5-	1(c)	) Transa	acti	ion Ind	ication					
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									to						
		Tab	le I - Non-De	rivativ	e Se	curities	s Ac	quired, [	Dis	posed o	f, or Be	neficiall	y Owned			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,		Code (Instr.   5)			Beneficia	es Form ally (D) o following (I) (In	n: Direct or Indirect Enstr. 4)	7. Nature of Indirect Beneficial Ownership				
					Code V Amount (A) or Pr				Price	Transact (Instr. 3 a	ion(s)		Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)  (Month/Day/Year)  7. Title and Amof Securities Underlying Derivative Securities (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$2.91	04/21/2023		A		50,000		(1)	0	04/20/2033	Common Stock	50,000	\$0	50,000	D	

## **Explanation of Responses:**

1. The options vest over 48 substantially equal monthly installments starting May 21, 2023.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

/s/ Neil Lerner, attorney-in-fact 04/24/2023

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.